New diabetes treatment enters the clinical trial stage with ASC36.
- ASC36 aims to address diabetes management
- Focus on oral peptide agonist
- Enters clinical trial phase
Ascletis has selected its oral amylin receptor peptide agonist, ASC36, for clinical development aimed at treating diabetes. This decision highlights the company's commitment to advancing new therapeutic options for diabetes management. ASC36 is designed to mimic the natural hormone amylin, which plays a crucial role in glycemic control.
The company plans to initiate clinical trials for ASC36 soon, following the selection as a promising candidate. This oral peptide agonist could offer a novel approach in the diabetes treatment landscape, focusing on improving glucose regulation. Ascletis aims to leverage the unique properties of this therapy to address unmet needs in diabetes management.
ASC36 has shown potential in preclinical studies, demonstrating desirable effects on glucose metabolism and insulin sensitivity. The progression to clinical trials marks an important step for Ascletis in developing innovative therapies that could significantly impact the lives of individuals living with diabetes.
